Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 41Carcinoma, Renal Cell 31Neoplasms 18Kidney Neoplasms 17Neuroendocrine Tumors 16Neoplasm Metastasis 13Tuberous Sclerosis 10Prostatic Neoplasms 8Carcinoma 8Lymphoma, Mantle-Cell 7Lymphoma, Large B-Cell, Diffuse 7Hodgkin Disease 7Glioma 7Glioblastoma 7Astrocytoma 7Waldenstrom Macroglobulinemia 6Triple Negative Breast Neoplasms 6Recurrence 6Lymphoma 6Head and Neck Neoplasms 6Stomach Neoplasms 5Ovarian Neoplasms 5Colorectal Neoplasms 5Carcinoma, Neuroendocrine 5Brain Neoplasms 5Sezary Syndrome 4Sarcoma 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Pancreatic Neoplasms 4Mycosis Fungoides 4

Interventions

Interferon alpha-2 1Everolimus 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Margins of Excision × Everolimus × Clear all
NCT00719264 2017-03-20

Safety and Efficacy of Bevacizumab Plus RAD001 Versus Interferon Alfa-2a and Bevacizumab for the First-line Treatment in Adult Patients With Kidney Cancer

Novartis

Phase 2 Completed
365 enrolled 14 charts
Genitourinary

Margins of Excision, Adenocarcinoma, Carcinoma, Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡